Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Pisciotta, Livia; Bellocchio, Antonella; Bertolini, Stafano // Lipids in Health & Disease;2012, Vol. 11 Issue 1, p123
Background: Although statins (STs) are drugs of first choice in hypercholesterolemic patients, especially in those at high cardiovascular risk, some of them are intolerant to STs or refuse treatment with these drugs. In view of this, we have evaluated the lipid-lowering effect of a nutraceutical...
- Diltiazem/simvastatin interaction. // Reactions Weekly;2/19/2011, Issue 1339, p18
The article describes the case of a 59-year-old man who developed rhabdomyolysis after receiving concomitant oral simvastatin for hypercolesterolemia and coronary heart disease and oral diltiazem for angina pectoris.
- Blood Lipids. Tolmach Sugerman, Deborah // JAMA: Journal of the American Medical Association;10/23/2013, Vol. 310 Issue 16, p1751
This article provides information on hyperlipidemia and discusses the types of blood lipids. Problems from hyperlipidemia include the risk of developing metabolic syndrome, diabetes and heart diseases. Lifestyle treatments for hyperlipidemia include eating a healthy, low-fat diet and exercise....
- Rhabdomyolysis in Community Acquired Bacterial Sepsis - A Retrospective Cohort Study. Kumar, Anita A.; Bhaskar, Emmanuel; Shantha, Ghanshyam Palamaner Subash; Swaminathan, Porchelvan; Abraham, Georgi // PLoS ONE;2009, Vol. 4 Issue 9, p1
Background and Objectives: Rhabdomyolysis is often associated with sepsis and gram positive bacterial pathogens are reported to be the most frequent cause of sepsis induced rhabdomyolysis. We report the pattern of infecting bacterial pathogens and associated causal factors in a South-Indian...
- Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin. Catapano, Alberico L. // Current Vascular Pharmacology;Mar2012, Vol. 10 Issue 2, p257
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the most widely prescribed therapeutic class of drugs worldwide, with established clinical benefits both in terms of improving serum lipid profiles and reducing cardiovascular events and mortality. Although statins have a...
- Atorvastatin. // Reactions Weekly;8/13/2011, Issue 1364, p9
The article describes the case of a man who developed rhabdomyolysis during treatment with atorvastatin for his myocardial infarction.
- Atorvastatin/fusidic acid interaction. // Reactions Weekly;3/26/2011, Issue 1344, p8
The article describes the case of a 58-year-old man who developed rhabdomyolysis while receiving concomitant treatment with atorvastatin and fusidic acid therapy.
- Atorvastatin/simvastatin/fusidic acid interaction. // Reactions Weekly;7/24/2010, Issue 1311, p13
The article describes the cases of four patients with type 2 diabetes melliitus who developed rhabdomyolysis due to drug interaction between atorvastatin, simvastatin and fusidic acid.
- Statins, macrolides and rhabdomyolysis. // Australian Journal of Pharmacy;Dec2010, Vol. 91 Issue 1087, p39
The article focuses on the reports received by the Therapeutic Goods Administration (TGA) as of July 2010, which show that 80% of the patients who received statin and macrolide antibiotic had at least one risk factor for myopathy.